Vitamin D, Calcium Did Not Reduce Risk for Colorectal Adenoma Recurrence

Article

Patients with a prior history of colorectal adenomas saw no reduction in the risk for recurrence with the use of a daily supplement of vitamin D, calcium, or both.

Patients with a prior history of colorectal adenomas saw no reduction in the risk for recurrence with the use of a daily supplement of vitamin D, calcium, or both, according to the results of a study published in the New England Journal of Medicine.

“Contrary to our hypotheses, neither 1000 IU of vitamin D3 nor 1200 mg of calcium, taken daily alone or in combination, reduced the risk of colorectal adenomas,” wrote researcher John A. Baron, MD, of the University of North Carolina at Chapel Hill, and colleagues.

Based on epidemiologic data suggesting that higher levels of vitamin D and calcium reduced risk for colorectal neoplasia, Baron and colleagues designed this study to explore the use of daily supplementation of vitamin D, calcium, or both for the prevention of colorectal adenomas.

The study included 2,259 patients who had recently been diagnosed with adenomas and had no known polyps remaining after complete colonoscopy. The patients were randomly assigned to daily 1,000 IU vitamin D3, 1,200 mg calcium as carbonate, both, or neither. All patients underwent a follow-up colonoscopy 3 or 5 years from baseline.

About 88% of patients who underwent randomization reported taking 80% of their tablets during the first year of the trial with this number decreasing to about 74% by the final year of treatment. The mean increase in serum 25-hydroxyvitamin D levels was 7.93 ng/mL among those patients assigned to vitamin D.

During the follow-up period, 3,131 lesions that were “potentially neoplastic” were diagnosed in 1,301 of the study participants; 880 participants were ultimately diagnosed with adenomas (43%).

The use of daily supplementation had no significant effect on the risk for recurrence, even among those participants with lower baseline levels of serum 25-hydroxyvitamin D.

The risk ratio for participants assigned vitamin D compared with those who were not was 0.99 (95% confidence interval [CI], 0.89–1.09); the risk among those taking calcium compared with those who were not was 0.95 (95% CI, 0.85–1.06). The risk ratio among participants taking both supplements compared with those taking calcium alone was 1.01 (95% CI, 0.88–1.15) and compared with those taking neither was 0.93 (95% CI, 0.80–1.08).

“We have no ready explanation for the finding with regard to calcium supplementation, but the lack of an observational association between the risk of adenomas and baseline dietary calcium intake in our population supports it,” the researchers wrote. “Our findings with regard to vitamin D are not inconsistent with a modest chemopreventive potential, but they do not support the more marked chemopreventive effect that has sometimes been posited.”

A subgroup analysis did reveal a decreased risk for adenomas among participants assigned to calcium supplementation with lower body mass index; however, the researchers wrote that “because of the number of subgroups examined, this finding may be due to chance.”

Related Videos
Increasing screening for younger individuals who are at risk of colorectal cancer may help mitigate the rising early incidence of this disease.
Laparoscopy may reduce the degree of pain or length of hospital stay compared with open surgery for patients with colorectal cancer.
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
The toxicity profile of tislelizumab also appears to look better compared with chemotherapy in metastatic esophageal squamous cell carcinoma.